Isolates with Low-Level Vancomycin Resistance Associated with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia
Open Access
- 1 September 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (9) , 3039-3047
- https://doi.org/10.1128/aac.00422-06
Abstract
Low-level vancomycin-resistant Staphylococcus aureus (vancomycin-intermediate S. aureus [VISA] and heterogenous VISA [hVISA]) is increasingly reported and leads to glycopeptide treatment failure. Various phenotypic features have been reported for these isolates, but the genetic changes leading to hVISA and VISA have yet to be clearly determined. We assessed phenotypic, antibiotic resistance, and genomic changes by using genomic DNA microarray comparison and sequencing of selected loci in five pairs of clinical hVISA/VISA strains and the initial methicillin-resistant Staphylococcus aureus (MRSA) isolates obtained prior to vancomycin therapy. The isolates were from adult patients in Australia and New Zealand who had persistent MRSA bacteremia (>7 days) while receiving vancomycin therapy. In all cases, the initial isolates were found to be fully vancomycin-susceptible Staphylococcus aureus (VSSA). The hVISA/VISA phenotype was associated with increased cell wall thickness, reduced autolytic activity in four of five hVISA/VISA strains, and a striking reduction in biofilm formation compared to the parent strains in all pairs. All five pairs appeared to be isogenic, and genomic DNA microarray comparison suggested that major genetic changes are not required for the development of the resistant phenotype in these strains. No sequence differences were found in the agr locus or the tcaRA genes for any pair, but a marked reduction in RNAIII expression was found in four pairs. In summary, hVISA/VISA arises from fully VSSA during persistent infection that fails to respond to glycopeptide therapy and is associated with significant phenotypic changes, including a marked reduction in biofilm-forming ability. These clinically derived pairs of isolates will be a useful resource to elucidate the genetic mechanism of resistance in hVISA/VISA strains.Keywords
This publication has 54 references indexed in Scilit:
- Autolytic Properties of Glycopeptide-Intermediate Staphylococcus aureus Mu50Antimicrobial Agents and Chemotherapy, 2006
- Novel Mechanism of Antibiotic Resistance Originating in Vancomycin-Intermediate Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2006
- Low-level vancomycin resistance in Staphylococcus aureus?an Australian perspectiveEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Alterations of Cell Wall Structure and MetabolismAccompany Reduced Susceptibility to Vancomycin in an IsogenicSeries of Clinical Isolates of StaphylococcusaureusJournal of Bacteriology, 2003
- Microarray Transcription Analysis of Clinical Staphylococcus aureus Isolates Resistant to VancomycinJournal of Bacteriology, 2003
- Vancomycin Treatment Failure Associated with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus in a Patient with Endocarditis and in the Rabbit Model of EndocarditisAntimicrobial Agents and Chemotherapy, 2003
- Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S . aureus under the Impact of Antibiotics Administered for ChemotherapyJournal of Clinical Microbiology, 2003
- The Prevalence and Mechanisms of Vancomycin Resistance in Staphylococcus AureusAnnual Review of Microbiology, 2002
- Impact of theagrQuorum‐Sensing System on Adherence to Polystyrene inStaphylococcus aureusThe Journal of Infectious Diseases, 2000
- Identification of the Up- and Down-Regulated Genes in Vancomycin-Resistant Staphylococcus aureus Strains Mu3 and Mu50 by cDNA Differential Hybridization MethodBiochemical and Biophysical Research Communications, 2000